Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; the references it cites are not checked yet.

An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)

Open access
Vacca, Michele, Kamzolas, Ioannis, Harder, Lea Mørch, Oakley, Fiona, Trautwein, Christian, Hatting, Maximilian, Ross, Trenton, Bernardo, Barbara, Oldenburger, Anouk, Hjuler, Sara Toftegaard, Ksiazek, Iwona, Lindén, Daniel, Schuppan, Detlef, Rodriguez-Cuenca, Sergio, Tonini, Maria Manuela, Castañeda, Tamara R., Kannt, Aimo, Rodrigues, Cecília M. P., Cockell, Simon, Govaere, Olivier, Daly, Ann K., Allison, Michael, Honnens de Lichtenberg, Kristian, Kim, Yong Ook, Lindblom, Anna, Oldham, Stephanie, Andréasson, Anne-Christine, Schlerman, Franklin, Marioneaux, Jonathon, Sanyal, Arun, Afonso, Marta B., Younes, Ramy, Amano, Yuichiro, Friedman, Scott L., Wang, Shuang, Bhattacharya, Dipankar, Simon, Eric, Paradis, Valérie, Burt, Alastair, Grypari, Ioanna Maria, Davies, Susan, Driessen, Ann, Yashiro, Hiroaki, Pors, Susanne, Worm Andersen, Maja, Feigh, Michael, Yunis, Carla, Bedossa, Pierre, Stewart, Michelle, Cater, Heather L., Wells, Sara, Schattenberg, Jörn M., Anstee, Quentin M., The LITMUS Investigators, Anstee, Quentin M., Daly, Ann K., Cockell, Simon, Tiniakos, Dina, Bedossa, Pierre, Burt, Alastair, Oakley, Fiona, Cordell, Heather J., Day, Christopher P., Wonders, Kristy, Missier, Paolo, McTeer, Matthew, Vale, Luke, Oluboyede, Yemi, Breckons, Matt, Boyle, Jo, Bossuyt, Patrick M., Zafarmand, Hadi, Vali, Yasaman, Lee, Jenny, Nieuwdorp, Max, Holleboom, Adriaan G., Angelakis, Athanasios, Verheij, Joanne, Ratziu, Vlad, Clément, Karine, Patino-Navarrete, Rafael, Pais, Raluca, Paradis, Valerie, Schuppan, Detlef, Schattenberg, Jörn M., Surabattula, Rambabu, Myneni, Sudha, Kim, Yong Ook, Straub, Beate K., Vidal-Puig, Antonio, Vacca, Michele, Rodrigues-Cuenca, Sergio, Allison, Mike, Kamzolas, Ioannis, Petsalaki, Evangelia, Campbell, Mark, Lelliott, Chris J., Davies, Susan, Orešič, Matej, Hyötyläinen, Tuulia, McGlinchey, Aidan, Mato, Jose M., Millet, Óscar, Dufour, Jean-François, Berzigotti, Annalisa, Masoodi, Mojgan, Lange, Naomi F., Pavlides, Michael, Harrison, Stephen, Neubauer, Stefan, Cobbold, Jeremy, Mozes, Ferenc, Akhtar, Salma, Olodo-Atitebi, Seliat, Banerjee, Rajarshi, Shumbayawonda, Elizabeth, Dennis, Andrea, Andersson, Anneli, Wigley, Ioan, Romero-Gómez, Manuel, Gómez-González, Emilio, Ampuero, Javier, Castell, Javier, Gallego-Durán, Rocío, Fernández-Lizaranzu, Isabel, Montero-Vallejo, Rocío, Karsdal, Morten, Rasmussen, Daniel Guldager Kring, Leeming, Diana Julie, Sinisi, Antonia, Musa, Kishwar, Sandt, Estelle, Tonini, Maria Manuela, Bugianesi, Elisabetta, Rosso, Chiara, Armandi, Angelo, Marra, Fabio, Gastaldelli, Amalia, Svegliati, Gianluca, Boursier, Jérôme, Francque, Sven, Vonghia, Luisa, Verrijken, An, Dirinck, Eveline, Driessen, Ann, Ekstedt, Mattias, Kechagias, Stergios, Yki-Järvinen, Hannele, Porthan, Kimmo, Arola, Johanna, van Mil, Saskia, Papatheodoridis, George, Cortez-Pinto, Helena, Silva, Ana Paula, Rodrigues, Cecilia M. P., Valenti, Luca, Pelusi, Serena, Petta, Salvatore, Pennisi, Grazia, Miele, Luca, Liguori, Antonio, Geier, Andreas, Rau, Monika, Trautwein, Christian, Reißing, Johanna, Aithal, Guruprasad P., Francis, Susan, Palaniyappan, Naaventhan, Bradley, Christopher, Hockings, Paul, Schneider, Moritz, Newsome, Philip N., Hübscher, Stefan, Wenn, David, Magnanensi, Jeremy, Trylesinski, Aldo, Mayo, Rebeca, Alonso, Cristina, Duffin, Kevin, Perfield, James W., Chen, Yu, Hartman, Mark L., Yunis, Carla, Miller, Melissa, Chen, Yan, McLeod, Euan James, Ross, Trenton, Bernardo, Barbara, Schölch, Corinna, Ertle, Judith, Younes, Ramy, Coxson, Harvey, Simon, Eric, Gogain, Joseph, Ostroff, Rachel, Alexander, Leigh, Biegel, Hannah, Kjær, Mette Skalshøi, Harder, Lea Mørch, Al-Sari, Naba, Veidal, Sanne Skovgård, Oldenburger, Anouk, Ellegaard, Jens, Balp, Maria-Magdalena, Jennings, Lori, Martic, Miljen, Löffler, Jürgen, Applegate, Douglas, Torstenson, Richard, Lindén, Daniel, Fournier-Poizat, Céline, Llorca, Anne, Kalutkiewicz, Michael, Pepin, Kay, Ehman, Richard, Horan, Gerald, Ho, Gideon, Tai, Dean, Chng, Elaine, Xiao, Teng, Patterson, Scott D., Billin, Andrew, Doward, Lynda, Twiss, James, Thakker, Paresh, Derdak, Zoltan, Yashiro, Hiroaki, Landgren, Henrik, Lackner, Carolin, Gouw, Annette, Hytiroglou, Prodromos, Govaere, Olivier, Brass, Clifford, Tiniakos, Dina, Perfield, James W., Petsalaki, Evangelia, Davidsen, Peter, Vidal-Puig, Antonio · 2024 · Nature Metabolism

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease, encompasses steatosis and metabolic dysfunction-associated steatohepatitis (MASH), leading to cirrhosis and hepatocellular carcinoma. Preclinical MASLD research is mainly performed in rodents; however, the model that best recapitulates human disease is yet to be defined. We conducted a wide-ranging retrospective review (metabolic phenotype, liver histopathology, transcriptome benchmarked against humans) of murine models (mostly male) and ranked them using an unbiased MASLD ‘human proximity score’ to define their metabolic relevance and ability to induce MASH-fibrosis. Here, we show that Western diets align closely with human MASH; high cholesterol content, extended study duration and/or genetic manipulation of disease-promoting pathways are required to intensify liver damage and accelerate significant (F2+) fibrosis development. Choline-deficient models rapidly induce MASH-fibrosis while showing relatively poor translatability. Our ranking of commonly used MASLD models, based on their proximity to human MASLD, helps with the selection of appropriate in vivo models to accelerate preclinical research.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s42255-024-01043-6

Cites

Statistics

Figures

Fig. 1 Study design. In this study, we collected retrospective information from 598 animals (509 WT/GA mice, 89 WT/GA rats): 336 animals subjected to treatment (MASLD-inducing conditions: 315 animals; or CCl4: 21 animals) and 262 animals as controls for MASLD-inducing conditions (247 animals) or CCl4 (15 animals), returning 39 models (that is, study designs) aimed at modeling MASLD, and two time points for CCl4 (positive controls of MASLD-independent fibrosis). Details of the study designs (numerosity, species, background, genetic manipulation, diet, time point and room temperature) are provided in Supplementary Table 1. For all the studies, phenotypic information (Supplementary Table 5), centralized histopathology assessment (Supplementary Table 6) and liver transcriptomics (Supplementary Table 4) were available. These data were integrated into an unbiased binary score (MHPS) ranking the models in terms of their metabolic relevance and ability to induce MASH-fibrosis. Created with BioRender (agreement number GG26BHMS6Y).
Fig. 1 Study design. In this study, we collected retrospective information from 598 animals (509 WT/GA mice, 89 WT/GA rats): 336 animals subjected to treatment (MASLD-inducing conditions: 315 animals; or CCl4: 21 animals) and 262 animals as controls for MASLD-inducing conditions (247 animals) or CCl4 (15 animals), returning 39 models (that is, study designs) aimed at modeling MASLD, and two time points for CCl4 (positive controls of MASLD-independent fibrosis). Details of the study designs (numerosity, species, background, genetic manipulation, diet, time point and room temperature) are provided in Supplementary Table 1. For all the studies, phenotypic information (Supplementary Table 5), centralized histopathology assessment (Supplementary Table 6) and liver transcriptomics (Supplementary Table 4) were available. These data were integrated into an unbiased binary score (MHPS) ranking the models in terms of their metabolic relevance and ability to induce MASH-fibrosis. Created with BioRender (agreement number GG26BHMS6Y).CC BY · PubMed Central
Fig. 2 Phenotypic and histologic characterization of the models. Phenotypic changes observed in the MASLD models compared to their matched controls were profiled as the log2 fold change (log2FC) across measures of BW, blood triglycerides (TGs) and cholesterol, LW:BW% ratio, and ALT and AST. The red–blue color gradient indicates the level of increase–decrease of the measure in the MASLD models compared to their controls, while an asterisk indicates a significant change at P < 0.05 (two-sided Mann–Whitney U-test). The two panels of horizontal bars give an overview of the complete histological profiles, in which the total length indicates the activity score (CRN NAS) and fibrosis25. In addition, NAS components (steatosis, ballooning and inflammation) are represented by the stacked bar (yellow, green and blue, respectively) lengths. All models are grouped according to their macro-categories (detailed by the leftmost annotations). Source data
Fig. 2 Phenotypic and histologic characterization of the models. Phenotypic changes observed in the MASLD models compared to their matched controls were profiled as the log2 fold change (log2FC) across measures of BW, blood triglycerides (TGs) and cholesterol, LW:BW% ratio, and ALT and AST. The red–blue color gradient indicates the level of increase–decrease of the measure in the MASLD models compared to their controls, while an asterisk indicates a significant change at P < 0.05 (two-sided Mann–Whitney U-test). The two panels of horizontal bars give an overview of the complete histological profiles, in which the total length indicates the activity score (CRN NAS) and fibrosis25. In addition, NAS components (steatosis, ballooning and inflammation) are represented by the stacked bar (yellow, green and blue, respectively) lengths. All models are grouped according to their macro-categories (detailed by the leftmost annotations). Source dataCC BY · PubMed Central
Fig. 3 DRPs in human and murine MASLD. Selection of KEGG-affected pathways characterizing the ‘early disease development’, ‘all disease stages’ and ‘disease progression’ groups. The ‘early disease development’ group includes statistically significant (P < 0.05) modulated pathways in ‘mild vs controls’ but not in ‘moderate–severe vs mild’ human disease stages comparisons. The ‘all disease stages’ group includes statistically significant and homogeneously modulated pathways at all human disease stages (‘mild vs controls’ and ‘moderate–severe vs mild’ in both UCAM–VCU and EPoS); the ‘disease progression’ group includes homogeneously modulated and statistically significant pathways in ‘moderate–severe vs mild’ comparisons in both UCAM–VCU and EPoS but not in ‘mild vs controls’ comparisons. FGSEA calculated a normalized enrichment score (NES; the enrichment score normalized to mean enrichment of random samples of the same size) for each pathway and determined statistical significance using permutation testing (two-sided), adjusting for multiple comparisons to control the false discovery rate (FDR). The human and murine datasets are represented in a color-scale matrix showing the NES. * and $ symbols denote statistical significance ($, P < 0.05; *, FDR < 0.05). All models are grouped according to their macro-categories, as indicated by the panel on the top of the heatmap. Source data
Fig. 3 DRPs in human and murine MASLD. Selection of KEGG-affected pathways characterizing the ‘early disease development’, ‘all disease stages’ and ‘disease progression’ groups. The ‘early disease development’ group includes statistically significant (P < 0.05) modulated pathways in ‘mild vs controls’ but not in ‘moderate–severe vs mild’ human disease stages comparisons. The ‘all disease stages’ group includes statistically significant and homogeneously modulated pathways at all human disease stages (‘mild vs controls’ and ‘moderate–severe vs mild’ in both UCAM–VCU and EPoS); the ‘disease progression’ group includes homogeneously modulated and statistically significant pathways in ‘moderate–severe vs mild’ comparisons in both UCAM–VCU and EPoS but not in ‘mild vs controls’ comparisons. FGSEA calculated a normalized enrichment score (NES; the enrichment score normalized to mean enrichment of random samples of the same size) for each pathway and determined statistical significance using permutation testing (two-sided), adjusting for multiple comparisons to control the false discovery rate (FDR). The human and murine datasets are represented in a color-scale matrix showing the NES. * and $ symbols denote statistical significance ($, P < 0.05; *, FDR < 0.05). All models are grouped according to their macro-categories, as indicated by the panel on the top of the heatmap. Source dataCC BY · PubMed Central
Fig. 4 Agreement of murine DEGs and DRPs with human MASLD. Heatmap showing the agreement between murine MASLD models and human data based on the list of significant DEGs, DRPs, or the whole transcriptome. The percentage (%) of agreement between murine and human datasets defines the proportion of DEGs and DRPs statistically modulated and in the same direction compared to the human reference datasets (defined for ‘early disease development’, ‘all disease stages’ and ‘disease progression’ comparisons) or the proportion of DEGs statistically modulated and in the same direction compared to the human disease stage comparisons (defined for the whole transcriptome). All models are grouped according to their macro-categories as indicated in the graphic legend of the figure. Data are represented in a color-scale matrix showing the percentage of agreement and refer to DEGs (Supplementary Table 4; whole dataset or genes defined for ‘early disease development’, ‘all disease stages’ and ‘disease progression’, respectively) and DRPs (Fig. 3). In parenthesis, we show the results of the hypergeometric test (one-sided) performed on the same comparison groups, indicating the statistical significance (NS, non-significant (P > 0.05)). Source data
Fig. 4 Agreement of murine DEGs and DRPs with human MASLD. Heatmap showing the agreement between murine MASLD models and human data based on the list of significant DEGs, DRPs, or the whole transcriptome. The percentage (%) of agreement between murine and human datasets defines the proportion of DEGs and DRPs statistically modulated and in the same direction compared to the human reference datasets (defined for ‘early disease development’, ‘all disease stages’ and ‘disease progression’ comparisons) or the proportion of DEGs statistically modulated and in the same direction compared to the human disease stage comparisons (defined for the whole transcriptome). All models are grouped according to their macro-categories as indicated in the graphic legend of the figure. Data are represented in a color-scale matrix showing the percentage of agreement and refer to DEGs (Supplementary Table 4; whole dataset or genes defined for ‘early disease development’, ‘all disease stages’ and ‘disease progression’, respectively) and DRPs (Fig. 3). In parenthesis, we show the results of the hypergeometric test (one-sided) performed on the same comparison groups, indicating the statistical significance (NS, non-significant (P > 0.05)). Source dataCC BY · PubMed Central
Fig. 5 Highly performing genes in human and murine MASLD. Selection of statistically significant DEGs (complete list in Supplementary Table 4) enriching statistically significant modulated pathways (complete list in Fig. 3), thus being highly biologically relevant genes associated with the different stages of MASLD development or progression. To assess the statistical significance between the compared groups, a Wald test statistic (two-sided hypothesis testing) was deployed to compare the coefficients of explanatory variables in a regression model, representing the gene expression differences among the compared groups. The human and murine datasets are represented in a color-scale matrix showing the log2FC. * and $ symbols denote statistical significance ($, P < 0.05; *, adjusted P < 0.05 (Benjamini–Hochberg correction)). As the graphic legend indicates, all models were grouped according to their macro-categories. Source data
Fig. 5 Highly performing genes in human and murine MASLD. Selection of statistically significant DEGs (complete list in Supplementary Table 4) enriching statistically significant modulated pathways (complete list in Fig. 3), thus being highly biologically relevant genes associated with the different stages of MASLD development or progression. To assess the statistical significance between the compared groups, a Wald test statistic (two-sided hypothesis testing) was deployed to compare the coefficients of explanatory variables in a regression model, representing the gene expression differences among the compared groups. The human and murine datasets are represented in a color-scale matrix showing the log2FC. * and $ symbols denote statistical significance ($, P < 0.05; *, adjusted P < 0.05 (Benjamini–Hochberg correction)). As the graphic legend indicates, all models were grouped according to their macro-categories. Source dataCC BY · PubMed Central
Fig. 6 The MHPS—metabolic relevance and progressive MASLD. a,b, Comparison of the MASLD models, performed based on the MHPS that incorporates the PHPS (details in Supplementary Table 5), the HHPS (details in Supplementary Table 6) and the DHPS (see Supplementary Fig. 4). The average of these normalized scores (MHPS) ranks the murine models (from high to low) based on their metabolic relevance (a) or their ability to induce MASH-fibrosis (b). A detailed description of the different components is provided in Extended Data Figs. 3 and 4, respectively. For both a and b, the total length of the horizontal bars indicates the MHPS, while the length of the stacks within each bar indicates the relative contribution from the three evidence layers: PHPS, HHPS and DHPS. A reference panel to the right indicates BW (significant increases in red; decreases in blue) and fibrosis score (*). Macro-categories are indicated by the color panel to the left of the plots. c, Correlation among the two MHPS outputs (‘metabolic relevance’ vs ‘ability to induce MASH-fibrosis). Specific models are highlighted based on their performance within the two rankings. Yellow dots represent models that score high with both rankings and represent the best approximation to human MASH. Red dots are models that score highly for metabolic relevance but are less relevant for MASH-fibrosis. Grey dots are models that score highly for MASH-fibrosis but have less metabolic relevance. Panels a and b provide a specific reference to the position in the scatter. Source data
Fig. 6 The MHPS—metabolic relevance and progressive MASLD. a,b, Comparison of the MASLD models, performed based on the MHPS that incorporates the PHPS (details in Supplementary Table 5), the HHPS (details in Supplementary Table 6) and the DHPS (see Supplementary Fig. 4). The average of these normalized scores (MHPS) ranks the murine models (from high to low) based on their metabolic relevance (a) or their ability to induce MASH-fibrosis (b). A detailed description of the different components is provided in Extended Data Figs. 3 and 4, respectively. For both a and b, the total length of the horizontal bars indicates the MHPS, while the length of the stacks within each bar indicates the relative contribution from the three evidence layers: PHPS, HHPS and DHPS. A reference panel to the right indicates BW (significant increases in red; decreases in blue) and fibrosis score (*). Macro-categories are indicated by the color panel to the left of the plots. c, Correlation among the two MHPS outputs (‘metabolic relevance’ vs ‘ability to induce MASH-fibrosis). Specific models are highlighted based on their performance within the two rankings. Yellow dots represent models that score high with both rankings and represent the best approximation to human MASH. Red dots are models that score highly for metabolic relevance but are less relevant for MASH-fibrosis. Grey dots are models that score highly for MASH-fibrosis but have less metabolic relevance. Panels a and b provide a specific reference to the position in the scatter. Source dataCC BY · PubMed Central
Fig. 7 Key experimental components contributing to MHPS ‘metabolic relevance’ and ‘ability to induce MASH-fibrosis’ outputs. Relationship between study design parameters and the MHPS of metabolic relevance and ability to induce MASH-fibrosis evaluated by PLSR. a, VIP for each study parameter (among those detailed in Supplementary Table 1) for the two components of the model. Parameters contributing the most to the PLSR model are characterized by having VIPs > 1 (black solid line) in any of the two components of the model. b, Clustered heatmap of the most influential study parameters (VIP > 1), indicating their correlation with the MHPS metabolic relevance and ability to induce MASH-fibrosis (color-scale matrix showing a positive correlation represented in red; negative correlation represented in blue). Source data
Fig. 7 Key experimental components contributing to MHPS ‘metabolic relevance’ and ‘ability to induce MASH-fibrosis’ outputs. Relationship between study design parameters and the MHPS of metabolic relevance and ability to induce MASH-fibrosis evaluated by PLSR. a, VIP for each study parameter (among those detailed in Supplementary Table 1) for the two components of the model. Parameters contributing the most to the PLSR model are characterized by having VIPs > 1 (black solid line) in any of the two components of the model. b, Clustered heatmap of the most influential study parameters (VIP > 1), indicating their correlation with the MHPS metabolic relevance and ability to induce MASH-fibrosis (color-scale matrix showing a positive correlation represented in red; negative correlation represented in blue). Source dataCC BY · PubMed Central
Fig. 8 Effects of treatments in a selection of WD and choline-deficient models. Response of the best-ranked diet (GAN-C2), another WD (AMLN-C2) and a CDHFD (CDAHFD-F45) to treatments mimicking lifestyle intervention (CR, caloric restriction; REV, chow reversal) and semaglutide pharmacological treatment (SEMA, 30 nmol per kg per day). a, Simplified study designs (details in Supplementary Table 7). b, Effect on the phenotype and histology. Phenotypic changes observed in the treatment or dietary models compared to their matched dietary models or controls, respectively, were profiled as log2FC across measures of BW, blood TGs and cholesterol, LW:BW%, and ALT and AST. The red–blue color gradient indicates the level of increase–decrease of the measure in the models compared to their respective controls; * indicates statistical significance (P < 0.05; two-sided Mann–Whitney U-test). For the histological changes, the Mann–Whitney U-test was used to calculate P values for the differences in the ordinal scores (P < 0.05 are shown with *). The color scale indicates the signed P value: −log10(P value) for up-regulation and +log10(P value) for down-regulation. c, Effect of treatments on a selection of biologically relevant DEGs as described in Fig. 5. The human and murine datasets are represented in a color-scale matrix showing the log2FC. * and $ symbols denote statistical significance (two-sided Wald test statistic and adjustment for multiple testing using the Benjamini–Hochberg correction; $: P < 0.05; *: adjusted P < 0.05). d, Effect of treatments on pathways as described in Fig. 3. FGSEA calculated a NES for each pathway and determined statistical significance using permutation testing (two-sided), adjusting for multiple comparisons to control the FDR. The human and murine datasets are represented in a color-scale matrix showing the NES. $, P < 0.05; *, FDR < 0.05). Source data
Fig. 8 Effects of treatments in a selection of WD and choline-deficient models. Response of the best-ranked diet (GAN-C2), another WD (AMLN-C2) and a CDHFD (CDAHFD-F45) to treatments mimicking lifestyle intervention (CR, caloric restriction; REV, chow reversal) and semaglutide pharmacological treatment (SEMA, 30 nmol per kg per day). a, Simplified study designs (details in Supplementary Table 7). b, Effect on the phenotype and histology. Phenotypic changes observed in the treatment or dietary models compared to their matched dietary models or controls, respectively, were profiled as log2FC across measures of BW, blood TGs and cholesterol, LW:BW%, and ALT and AST. The red–blue color gradient indicates the level of increase–decrease of the measure in the models compared to their respective controls; * indicates statistical significance (P < 0.05; two-sided Mann–Whitney U-test). For the histological changes, the Mann–Whitney U-test was used to calculate P values for the differences in the ordinal scores (P < 0.05 are shown with *). The color scale indicates the signed P value: −log10(P value) for up-regulation and +log10(P value) for down-regulation. c, Effect of treatments on a selection of biologically relevant DEGs as described in Fig. 5. The human and murine datasets are represented in a color-scale matrix showing the log2FC. * and $ symbols denote statistical significance (two-sided Wald test statistic and adjustment for multiple testing using the Benjamini–Hochberg correction; $: P < 0.05; *: adjusted P < 0.05). d, Effect of treatments on pathways as described in Fig. 3. FGSEA calculated a NES for each pathway and determined statistical significance using permutation testing (two-sided), adjusting for multiple comparisons to control the FDR. The human and murine datasets are represented in a color-scale matrix showing the NES. $, P < 0.05; *, FDR < 0.05). Source dataCC BY · PubMed Central
Extended Data Fig. 1 PCA plot of RNASeq data comparing the different mouse MASLD models. The plot uses the normalised batch-corrected gene expression data. Each point represents a mouse model. The Controls (triangles) are clearly separated from the MASLD models (circles) according to the first principal component (PC1). Source data
Extended Data Fig. 1 PCA plot of RNASeq data comparing the different mouse MASLD models. The plot uses the normalised batch-corrected gene expression data. Each point represents a mouse model. The Controls (triangles) are clearly separated from the MASLD models (circles) according to the first principal component (PC1). Source dataCC BY · PubMed Central
Extended Data Fig. 2 PCA plot of RNASeq data comparing the different rat MASLD models. The plot uses the normalised batch-corrected gene expression data. Each point represents a rat model. The Controls (triangles) are separated from the MASLD models (circles) according to the first principal component (PC1). Source data
Extended Data Fig. 2 PCA plot of RNASeq data comparing the different rat MASLD models. The plot uses the normalised batch-corrected gene expression data. Each point represents a rat model. The Controls (triangles) are separated from the MASLD models (circles) according to the first principal component (PC1). Source dataCC BY · PubMed Central
Extended Data Fig. 3 Details of the MHPS components (PHPS, HHPS, DHPS) – Metabolic Relevance. Bar plots show the detailed composition of the MHPS components (PHPS, HHPS, and DHPS) utilised for the output focusing on metabolic relevance. Models are ordered globally according to the MHPS, where each barplot gives an overview of the total PHPS, HHPS or DHPS, the associated features, and their corresponding scores (see Supplementary Tables 5 and 6 and Supplementary Fig. 4 for an overview of the scoring strategies). For each model, the total scores of PHPS and HHPS are represented by red vertical lines to overcome the fact that some features are scored negatively. For PHPS and HHPS, the length of the stacked bars represents the scores’ absolute values (before normalising to the interval 0-1). DHPS directly shows the normalised score. Feature scores included are abbreviated as follows: PHPS: BW = Body weight, TG = Triglycerides, CL = Cholesterol, L/B = Liver Weight/Body weight (%), LE = Liver enzyme levels of ALT & AST; HHPS: C1 = Topography of histological lesions, C2 = Type of steatosis, C3 = Hepatocyte ballooning, C4 = Lobular inflammation, C5 = Mallory-Denk bodies; DHPS: DEG = Differentially Expressed Genes, DRP = Differentially Regulated Pathways. Source data
Extended Data Fig. 3 Details of the MHPS components (PHPS, HHPS, DHPS) – Metabolic Relevance. Bar plots show the detailed composition of the MHPS components (PHPS, HHPS, and DHPS) utilised for the output focusing on metabolic relevance. Models are ordered globally according to the MHPS, where each barplot gives an overview of the total PHPS, HHPS or DHPS, the associated features, and their corresponding scores (see Supplementary Tables 5 and 6 and Supplementary Fig. 4 for an overview of the scoring strategies). For each model, the total scores of PHPS and HHPS are represented by red vertical lines to overcome the fact that some features are scored negatively. For PHPS and HHPS, the length of the stacked bars represents the scores’ absolute values (before normalising to the interval 0-1). DHPS directly shows the normalised score. Feature scores included are abbreviated as follows: PHPS: BW = Body weight, TG = Triglycerides, CL = Cholesterol, L/B = Liver Weight/Body weight (%), LE = Liver enzyme levels of ALT & AST; HHPS: C1 = Topography of histological lesions, C2 = Type of steatosis, C3 = Hepatocyte ballooning, C4 = Lobular inflammation, C5 = Mallory-Denk bodies; DHPS: DEG = Differentially Expressed Genes, DRP = Differentially Regulated Pathways. Source dataCC BY · PubMed Central
Extended Data Fig. 4 Details of the MHPS components (PHPS, HHPS, DHPS) – Ability to induce MASH-Fibrosis. Bar plots show the detailed composition of the MHPS components (PHPS, HHPS, and DHPS) for the output focusing on the ability to induce MASH-Fibrosis. Models are ordered globally according to the MHPS, where each barplot gives an overview of the total PHPS, HHPS or DHPS, associated features, and corresponding scores (see Supplementary Tables 5 and 6 and Supplementary Fig. 4 for an overview of the scoring strategies). For each model, the total scores of PHPS and HHPS are represented by red vertical lines to overcome the fact that some features are scored negatively. For PHPS and HHPS, the length of the stacked bars represents absolute scores' absolute values (before normalising to the interval 0-1). DHPS shows the normalised score directly. Feature scores included are abbreviated as follows: PHPS: BW = Body weight, TG = Triglycerides, CL = Cholesterol, L/B = Liver Weight/Body weight (%), LE = Liver enzyme levels of ALT & AST; HHPS: C1 = Topography of histological lesions, C2 = Type of steatosis, C3 = Hepatocyte ballooning, C4 = Lobular inflammation, C5 = Mallory-Denk bodies, F(C6) = Fibrosis; and for DHPS: DEG = Differentially Expressed Genes, DRP = Differentially Regulated Pathways. Source data
Extended Data Fig. 4 Details of the MHPS components (PHPS, HHPS, DHPS) – Ability to induce MASH-Fibrosis. Bar plots show the detailed composition of the MHPS components (PHPS, HHPS, and DHPS) for the output focusing on the ability to induce MASH-Fibrosis. Models are ordered globally according to the MHPS, where each barplot gives an overview of the total PHPS, HHPS or DHPS, associated features, and corresponding scores (see Supplementary Tables 5 and 6 and Supplementary Fig. 4 for an overview of the scoring strategies). For each model, the total scores of PHPS and HHPS are represented by red vertical lines to overcome the fact that some features are scored negatively. For PHPS and HHPS, the length of the stacked bars represents absolute scores' absolute values (before normalising to the interval 0-1). DHPS shows the normalised score directly. Feature scores included are abbreviated as follows: PHPS: BW = Body weight, TG = Triglycerides, CL = Cholesterol, L/B = Liver Weight/Body weight (%), LE = Liver enzyme levels of ALT & AST; HHPS: C1 = Topography of histological lesions, C2 = Type of steatosis, C3 = Hepatocyte ballooning, C4 = Lobular inflammation, C5 = Mallory-Denk bodies, F(C6) = Fibrosis; and for DHPS: DEG = Differentially Expressed Genes, DRP = Differentially Regulated Pathways. Source dataCC BY · PubMed Central
Extended Data Fig. 5 Representative images of MASLD histopathology features in the 6NTAC-GAN-C2-TN42W model. a. Panlobular distribution of steatosis, grade 3, H&E stain, x50; b. Ballooned hepatocyte (arrow), H&E stain, x200; c. Necroinflammatory focus (arrowhead), H&E stain, x200; d. Periportal and extensive sinusoidal fibrosis, stage 2, Sirius red stain, x50 (THV terminal hepatic venule, PT portal tract).
Extended Data Fig. 5 Representative images of MASLD histopathology features in the 6NTAC-GAN-C2-TN42W model. a. Panlobular distribution of steatosis, grade 3, H&E stain, x50; b. Ballooned hepatocyte (arrow), H&E stain, x200; c. Necroinflammatory focus (arrowhead), H&E stain, x200; d. Periportal and extensive sinusoidal fibrosis, stage 2, Sirius red stain, x50 (THV terminal hepatic venule, PT portal tract).CC BY · PubMed Central
Extended Data Fig. 6 Representative images of MASLD histopathology features in the 6NTAC-GAN-C2-RT42W model. a. Panlobular distribution of steatosis, grade 3, H&E stain, x50; b. Necroinflammatory foci (arrowheads), H&E stain, x200; c. Ballooned Hepatocyte (arrow), H&E stain, x200; d. Periportal and perisinusoidal fibrosis, stage 2, Sirius red stain, x50 (THV terminal hepatic venule, PT portal tract).
Extended Data Fig. 6 Representative images of MASLD histopathology features in the 6NTAC-GAN-C2-RT42W model. a. Panlobular distribution of steatosis, grade 3, H&E stain, x50; b. Necroinflammatory foci (arrowheads), H&E stain, x200; c. Ballooned Hepatocyte (arrow), H&E stain, x200; d. Periportal and perisinusoidal fibrosis, stage 2, Sirius red stain, x50 (THV terminal hepatic venule, PT portal tract).CC BY · PubMed Central
Extended Data Fig. 7 Representative images of MASLD histopathology features in the AZ-OB-GAN-23W model. a. Panlobular distribution of steatosis, grade 3, H&E stain, x50; b. Non-classical ballooned hepatocyte (arrow) and necroinflammatory foci (arrowheads), H&E stain, x200; c. Periportal and perisinusoidal fibrosis, stage 2, Sirius red stain, x50 (THV terminal hepatic venule, PT portal tract).
Extended Data Fig. 7 Representative images of MASLD histopathology features in the AZ-OB-GAN-23W model. a. Panlobular distribution of steatosis, grade 3, H&E stain, x50; b. Non-classical ballooned hepatocyte (arrow) and necroinflammatory foci (arrowheads), H&E stain, x200; c. Periportal and perisinusoidal fibrosis, stage 2, Sirius red stain, x50 (THV terminal hepatic venule, PT portal tract).CC BY · PubMed Central
Extended Data Fig. 8 Representative images of MASLD histopathology features in the OB-GAN-C2-12W model. a. Panlobular distribution of steatosis, grade 3, H&E stain, x50; b. Necroinflammatory focus (arrowhead), H&E stain, x200; c. Ballooned hepatocyte (arrow), H&E stain, x200; d. Periportal and perisinusoidal fibrosis, stage 2, Sirius red stain, x50 (THV terminal hepatic venule, PT portal tract).
Extended Data Fig. 8 Representative images of MASLD histopathology features in the OB-GAN-C2-12W model. a. Panlobular distribution of steatosis, grade 3, H&E stain, x50; b. Necroinflammatory focus (arrowhead), H&E stain, x200; c. Ballooned hepatocyte (arrow), H&E stain, x200; d. Periportal and perisinusoidal fibrosis, stage 2, Sirius red stain, x50 (THV terminal hepatic venule, PT portal tract).CC BY · PubMed Central
Extended Data Fig. 9 Representative images of MASLD histopathology features in the MC4R-WD-C0.2-21W model. a. Panlobular distribution of steatosis, grade 3, H&E stain, x50; b. Necroinflammatory foci (arrowheads), H&E stain, x200; c. Ballooned hepatocytes (arrows), H&E stain, x200; d. Periportal and perisinusoidal fibrosis, stage 2, Sirius red fast green stain, x50 (THV terminal hepatic venule, PT portal tract).
Extended Data Fig. 9 Representative images of MASLD histopathology features in the MC4R-WD-C0.2-21W model. a. Panlobular distribution of steatosis, grade 3, H&E stain, x50; b. Necroinflammatory foci (arrowheads), H&E stain, x200; c. Ballooned hepatocytes (arrows), H&E stain, x200; d. Periportal and perisinusoidal fibrosis, stage 2, Sirius red fast green stain, x50 (THV terminal hepatic venule, PT portal tract).CC BY · PubMed Central
Extended Data Fig. 10 Representative images of MASLD histopathology features in the LDLR-CDHFHCD-F42-C1-8W model. a. Panlobular distribution of steatosis, grade 3, H&E stain, x50; b. Periportal and perisinusoidal fibrosis, stage 2, Sirius red stain, x50; c) Necroinflammatory foci (arrowheads), H&E stain, x200; d. Ballooned hepatocyte (arrow), H&E stain, x200 THV terminal hepatic venule, PT portal tract).
Extended Data Fig. 10 Representative images of MASLD histopathology features in the LDLR-CDHFHCD-F42-C1-8W model. a. Panlobular distribution of steatosis, grade 3, H&E stain, x50; b. Periportal and perisinusoidal fibrosis, stage 2, Sirius red stain, x50; c) Necroinflammatory foci (arrowheads), H&E stain, x200; d. Ballooned hepatocyte (arrow), H&E stain, x200 THV terminal hepatic venule, PT portal tract).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 60 · Cited by 262

Metadata

Authors
Vacca, M., Kamzolas, I., Harder, L. M., Oakley, F., Trautwein, C., Hatting, M., Ross, T., Bernardo, B., Oldenburger, A., Hjuler, S. T., Ksiazek, I., Lindén, D., Schuppan, D., Rodriguez-Cuenca, S., Tonini, M. M., Castañeda, T. R., Kannt, A., Rodrigues, C. M. P., Cockell, S., Govaere, O., Daly, A. K., Allison, M., Honnens de Lichtenberg, K., Kim, Y. O., Lindblom, A., Oldham, S., Andréasson, A.-C., Schlerman, F., Marioneaux, J., Sanyal, A., Afonso, M. B., Younes, R., Amano, Y., Friedman, S. L., Wang, S., Bhattacharya, D., Simon, E., Paradis, V., Burt, A., Grypari, I. M., Davies, S., Driessen, A., Yashiro, H., Pors, S., Worm Andersen, M., Feigh, M., Yunis, C., Bedossa, P., Stewart, M., Cater, H. L., Wells, S., Schattenberg, J. M., Anstee, Q. M., The LITMUS Investigators, Anstee, Q. M., Daly, A. K., Cockell, S., Tiniakos, D., Bedossa, P., Burt, A., Oakley, F., Cordell, H. J., Day, C. P., Wonders, K., Missier, P., McTeer, M., Vale, L., Oluboyede, Y., Breckons, M., Boyle, J., Bossuyt, P. M., Zafarmand, H., Vali, Y., Lee, J., Nieuwdorp, M., Holleboom, A. G., Angelakis, A., Verheij, J., Ratziu, V., Clément, K., Patino-Navarrete, R., Pais, R., Paradis, V., Schuppan, D., Schattenberg, J. M., Surabattula, R., Myneni, S., Kim, Y. O., Straub, B. K., Vidal-Puig, A., Vacca, M., Rodrigues-Cuenca, S., Allison, M., Kamzolas, I., Petsalaki, E., Campbell, M., Lelliott, C. J., Davies, S., Orešič, M., Hyötyläinen, T., McGlinchey, A., Mato, J. M., Millet, Ó., Dufour, J.-F., Berzigotti, A., Masoodi, M., Lange, N. F., Pavlides, M., Harrison, S., Neubauer, S., Cobbold, J., Mozes, F., Akhtar, S., Olodo-Atitebi, S., Banerjee, R., Shumbayawonda, E., Dennis, A., Andersson, A., Wigley, I., Romero-Gómez, M., Gómez-González, E., Ampuero, J., Castell, J., Gallego-Durán, R., Fernández-Lizaranzu, I., Montero-Vallejo, R., Karsdal, M., Rasmussen, D. G. K., Leeming, D. J., Sinisi, A., Musa, K., Sandt, E., Tonini, M. M., Bugianesi, E., Rosso, C., Armandi, A., Marra, F., Gastaldelli, A., Svegliati, G., Boursier, J., Francque, S., Vonghia, L., Verrijken, A., Dirinck, E., Driessen, A., Ekstedt, M., Kechagias, S., Yki-Järvinen, H., Porthan, K., Arola, J., van Mil, S., Papatheodoridis, G., Cortez-Pinto, H., Silva, A. P., Rodrigues, C. M. P., Valenti, L., Pelusi, S., Petta, S., Pennisi, G., Miele, L., Liguori, A., Geier, A., Rau, M., Trautwein, C., Reißing, J., Aithal, G. P., Francis, S., Palaniyappan, N., Bradley, C., Hockings, P., Schneider, M., Newsome, P. N., Hübscher, S., Wenn, D., Magnanensi, J., Trylesinski, A., Mayo, R., Alonso, C., Duffin, K., Perfield, J. W., Chen, Y., Hartman, M. L., Yunis, C., Miller, M., Chen, Y., McLeod, E. J., Ross, T., Bernardo, B., Schölch, C., Ertle, J., Younes, R., Coxson, H., Simon, E., Gogain, J., Ostroff, R., Alexander, L., Biegel, H., Kjær, M. S., Harder, L. M., Al-Sari, N., Veidal, S. S., Oldenburger, A., Ellegaard, J., Balp, M.-M., Jennings, L., Martic, M., Löffler, J., Applegate, D., Torstenson, R., Lindén, D., Fournier-Poizat, C., Llorca, A., Kalutkiewicz, M., Pepin, K., Ehman, R., Horan, G., Ho, G., Tai, D., Chng, E., Xiao, T., Patterson, S. D., Billin, A., Doward, L., Twiss, J., Thakker, P., Derdak, Z., Yashiro, H., Landgren, H., Lackner, C., Gouw, A., Hytiroglou, P., Govaere, O., Brass, C., Tiniakos, D., Perfield, J. W., Petsalaki, E., Davidsen, P., & Vidal-Puig, A.
Affiliations
  • Universitätsklinikum Aachen (DE)
  • Novo Nordisk (Denmark) (DK)
  • Novartis (Switzerland) (CH)
  • Sanofi (Germany) (DE)
  • Goethe University Frankfurt (DE)
  • Cambridge University Hospitals NHS Foundation Trust (GB)
  • AstraZeneca (Sweden) (SE)
  • AstraZeneca (United States) (US)
  • Pfizer (United States) (US)
  • Virginia Commonwealth University (US)
  • University of Lisbon (PT)
  • Takeda (Japan) (JP)
  • Icahn School of Medicine at Mount Sinai (US)
  • National and Kapodistrian University of Athens (GR)
  • Gubra (Denmark) (DK)
  • Mary Lyon Centre at MRC Harwell (GB)
  • NIHR Newcastle Biomedical Research Centre (GB)
  • Newcastle University (GB)
  • Amsterdam UMC Location University of Amsterdam (NL)
  • Fondation pour l’innovation en Cadiométabolisme et Nutrition (FR)
  • Hôpital Beaujon (FR)
  • University Medical Center of the Johannes Gutenberg University Mainz (DE)
  • University of Cambridge (GB)
  • Örebro University (SE)
  • University of Bern (CH)
  • University of Oxford (GB)
  • Perspectum Ltd. (United Kingdom) (GB)
  • Andalusian Health Service (ES)
  • Nordic Bioscience (Denmark) (DK)
  • Integrated Biobank of Luxembourg (LU)
  • University of Turin (IT)
  • University of Florence (IT)
  • National Research Council (IT)
  • Marche Polytechnic University (IT)
  • Antwerp University Hospital (BE)
  • Linköping University (SE)
  • University of Helsinki (FI)
  • University of Milan (IT)
  • University of Palermo (IT)
  • Università Cattolica del Sacro Cuore (IT)
  • Universitätsklinikum Würzburg (DE)
  • University of Nottingham (GB)
  • Antaros Medical (Sweden) (SE)
  • University Hospitals Birmingham NHS Foundation Trust (GB)
  • iXscient (GB)
  • Intercept Pharmaceuticals (United States) (US)
  • Eli Lilly (United States) (US)
  • Boehringer Ingelheim (Germany) (DE)
  • SomaLogic (United States) (US)
  • Echosens (France) (FR)
  • Bristol-Myers Squibb (United States) (US)
  • Histoindex (Singapore) (SG)
  • Gilead Sciences (United States) (US)
  • Medical University of Graz (AT)
  • University of Groningen (NL)
  • Aristotle University of Thessaloniki (GR)
Corresponding author
Davidsen, Peter
ORCID
Venue
Nature Metabolism
Published
2024-06-12
Volume
6
Issue
6
Pages
1178-1196
ISSN
2522-5812 (ISSN-L)
OpenAlex
W4399578202
Cited by
262
References
60
Citations by year
2026: 101 · 2025: 115 · 2024: 46
FWCI
79.04
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Metabolism (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
  • Lirias (submittedVersion, cc-by)
  • PubliCatt (Università Cattolica del Sacro Cuore) (submittedVersion, cc-by)
  • Pure Amsterdam UMC (submittedVersion, cc-by)
  • CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, cc-by)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
  • DiVA (Linkoping University) (submittedVersion, other-oa)
  • HAL (submittedVersion)
  • Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
  • Työväentutkimus Vuosikirja (submittedVersion)
  • Fraunhofer-Publica (Fraunhofer-Gesellschaft) (submittedVersion, other-oa)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
  • Apollo (cc-by)
  • RWTH Publications (RWTH Aachen)
Funders
  • Innovative Medicines Initiative (777377)
  • Associazione Italiana per la Ricerca sul Cancro (IG27521)
  • Universita degli Studi di Bari Aldo Moro (S06-miRNASH)
  • Ministero dellapos;Istruzione, dellapos;Universit e della Ricerca (P202222FCC, PE00000003, CN00000041, CN00000013)
  • Foundation for Liver Research (Intramural)
  • RCUK | Medical Research Council (1948243, MR/R023026/1, MR/K0019494/1)
  • Fundacin Espaola para la Ciencia y la Tecnologa (PTDC/MED-FAR/3492/2021)
  • la Caixa Foundation (LCF/PR/HR21/52410028)
  • U.S. Department of Health Human Services | NIH | NIH Clinical Center (NIH R01 DK128289, NCI 5P30CA196521-08, NIH R01 DK136016)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, murine disease models, model ranking, choline-deficient diet, liver fibrosis, liver histopathology, transcriptome comparison
MeSH terms
Animals, Disease Models, Animal, Humans, Liver, Liver Cirrhosis, Male, Metabolic Diseases, Retrospective Studies, Mice, Non-alcoholic Fatty Liver Disease, Diet, Western

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD). https://app.cochat.ai/papers/10.1038/s42255-024-01043-6
The paper
Vacca, M., Kamzolas, I., Harder, L. M., Oakley, F., Trautwein, C., Hatting, M., Ross, T., Bernardo, B., Oldenburger, A., Hjuler, S. T., Ksiazek, I., Lindén, D., Schuppan, D., Rodriguez-Cuenca, S., Tonini, M. M., Castañeda, T. R., Kannt, A., Rodrigues, C. M. P., Cockell, S., . . . Vidal-Puig, A. (2024). An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD). Nature Metabolism. https://doi.org/10.1038/s42255-024-01043-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.